Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

E-ISSN： 1097-0142|121|19|3390-3392

ISSN： 0008-543X

Source： Cancer, Vol.121, Iss.19, 2015-10, pp. : 3390-3392

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR pathway inhibitors in cancer therapy: moving past rapamycin

By Wacheck Volker

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1189-1191

Future Medicine

Access to resources Recommend Favorite

mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy

Current Cancer Drug Targets, Vol. 8, Iss. 8, 2008-12 ,pp. : 647-665

Bentham Science Publishers

Access to resources Recommend Favorite

An overview of the mTOR pathway as a target in cancer therapy

By Gentzler Ryan D Altman Jessica K Platanias Leonidas C

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 5, 2012-05 ,pp. : 481-489

Informa Healthcare

Access to resources Recommend Favorite

The mTOR Pathway: A New Target in Cancer Therapy

Current Cancer Drug Targets, Vol. 10, Iss. 5, 2010-08 ,pp. : 484-495

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR inhibitors in the treatment of cancer

By Fasolo Angelica Sessa Cristiana

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1717-1734

Informa Healthcare

Access to resources Recommend Favorite